Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan

Yoko Okunuki, Yoshihiko Usui, Norihiro Nagai, Takeshi Kezuka, Susumu Ishida, Masaru Takeuchi, Hiroshi Goto

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

PURPOSE. Angiotensin II type 1 receptor (AT1-R) blockers are used widely for the treatment of patients with hypertension. Recent reports have suggested that AT1-R also plays a key role in various inflammatory conditions. The aim of this study was to examine whether blockade of AT1-R is effective in the suppression of murine experimental autoimmune uveoretinitis (EAU). METHODS. C57BL/6 mice were immunized with human interphotoreceptor retinoid binding protein-derived peptide 1-20 (hIRBP-p). Telmisartan, an AT1-R blocker, was administrated daily by intraperitoneal injection. On day 21 after immunization, the severity of EAU was assessed clinically and histopathologically. With the use of flow cytometry, the activation of draining lymph node (LN) cells was assessed by cell proliferation response against hIRBP-p and by the number of CD44high activated CD4+ T cells present. In addition, mRNA expression of ICAM-1, MCP-1, and IFN-γ in the eye was analyzed by reverse-transcriptase PCR, and the number of retinal adherent leukocytes was counted by retinal perfusion labeling. RESULTS. Telmisartan significantly suppressed EAU clinically and histopathologically. Intraocular mRNA expression of ICAM-1 and MCP-1 was downregulated, and the retinal adherent leukocyte counts were significantly decreased in telmisartan-treated mice compared with vehicle-treated mice. LN cell proliferative responses against hIRBP-p and the number of CD44highCD4+ T cells were remarkably reduced in telmisartan-treated mice. CONCLUSIONS. Systemic administration of telmisartan significantly suppressed EAU by the inhibition of antigen-specific T-cell activation in the LNs and of leukocyte adhesion in the retina. These results indicate that telmisartan may be a novel therapeutic regimen for patients with endogenous uveitis.

Original languageEnglish
Pages (from-to)2255-2261
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume50
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Angiotensin II Type 1 Receptor Blockers
Uveitis
Angiotensin Type 1 Receptor
Intercellular Adhesion Molecule-1
Peptides
Leukocytes
Lymph Nodes
CD27 Antigens
T-Lymphocytes
Messenger RNA
Intraperitoneal Injections
Reverse Transcriptase Polymerase Chain Reaction
Leukocyte Count
Inbred C57BL Mouse
Retina
telmisartan
Immunization
Flow Cytometry
Down-Regulation
Perfusion

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. / Okunuki, Yoko; Usui, Yoshihiko; Nagai, Norihiro; Kezuka, Takeshi; Ishida, Susumu; Takeuchi, Masaru; Goto, Hiroshi.

In: Investigative Ophthalmology and Visual Science, Vol. 50, No. 5, 2009, p. 2255-2261.

Research output: Contribution to journalArticle

Okunuki, Yoko ; Usui, Yoshihiko ; Nagai, Norihiro ; Kezuka, Takeshi ; Ishida, Susumu ; Takeuchi, Masaru ; Goto, Hiroshi. / Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. In: Investigative Ophthalmology and Visual Science. 2009 ; Vol. 50, No. 5. pp. 2255-2261.
@article{51cde08db0804c6299cfb1034af06421,
title = "Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan",
abstract = "PURPOSE. Angiotensin II type 1 receptor (AT1-R) blockers are used widely for the treatment of patients with hypertension. Recent reports have suggested that AT1-R also plays a key role in various inflammatory conditions. The aim of this study was to examine whether blockade of AT1-R is effective in the suppression of murine experimental autoimmune uveoretinitis (EAU). METHODS. C57BL/6 mice were immunized with human interphotoreceptor retinoid binding protein-derived peptide 1-20 (hIRBP-p). Telmisartan, an AT1-R blocker, was administrated daily by intraperitoneal injection. On day 21 after immunization, the severity of EAU was assessed clinically and histopathologically. With the use of flow cytometry, the activation of draining lymph node (LN) cells was assessed by cell proliferation response against hIRBP-p and by the number of CD44high activated CD4+ T cells present. In addition, mRNA expression of ICAM-1, MCP-1, and IFN-γ in the eye was analyzed by reverse-transcriptase PCR, and the number of retinal adherent leukocytes was counted by retinal perfusion labeling. RESULTS. Telmisartan significantly suppressed EAU clinically and histopathologically. Intraocular mRNA expression of ICAM-1 and MCP-1 was downregulated, and the retinal adherent leukocyte counts were significantly decreased in telmisartan-treated mice compared with vehicle-treated mice. LN cell proliferative responses against hIRBP-p and the number of CD44highCD4+ T cells were remarkably reduced in telmisartan-treated mice. CONCLUSIONS. Systemic administration of telmisartan significantly suppressed EAU by the inhibition of antigen-specific T-cell activation in the LNs and of leukocyte adhesion in the retina. These results indicate that telmisartan may be a novel therapeutic regimen for patients with endogenous uveitis.",
author = "Yoko Okunuki and Yoshihiko Usui and Norihiro Nagai and Takeshi Kezuka and Susumu Ishida and Masaru Takeuchi and Hiroshi Goto",
year = "2009",
doi = "10.1167/iovs.08-2649",
language = "English",
volume = "50",
pages = "2255--2261",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "5",

}

TY - JOUR

T1 - Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan

AU - Okunuki, Yoko

AU - Usui, Yoshihiko

AU - Nagai, Norihiro

AU - Kezuka, Takeshi

AU - Ishida, Susumu

AU - Takeuchi, Masaru

AU - Goto, Hiroshi

PY - 2009

Y1 - 2009

N2 - PURPOSE. Angiotensin II type 1 receptor (AT1-R) blockers are used widely for the treatment of patients with hypertension. Recent reports have suggested that AT1-R also plays a key role in various inflammatory conditions. The aim of this study was to examine whether blockade of AT1-R is effective in the suppression of murine experimental autoimmune uveoretinitis (EAU). METHODS. C57BL/6 mice were immunized with human interphotoreceptor retinoid binding protein-derived peptide 1-20 (hIRBP-p). Telmisartan, an AT1-R blocker, was administrated daily by intraperitoneal injection. On day 21 after immunization, the severity of EAU was assessed clinically and histopathologically. With the use of flow cytometry, the activation of draining lymph node (LN) cells was assessed by cell proliferation response against hIRBP-p and by the number of CD44high activated CD4+ T cells present. In addition, mRNA expression of ICAM-1, MCP-1, and IFN-γ in the eye was analyzed by reverse-transcriptase PCR, and the number of retinal adherent leukocytes was counted by retinal perfusion labeling. RESULTS. Telmisartan significantly suppressed EAU clinically and histopathologically. Intraocular mRNA expression of ICAM-1 and MCP-1 was downregulated, and the retinal adherent leukocyte counts were significantly decreased in telmisartan-treated mice compared with vehicle-treated mice. LN cell proliferative responses against hIRBP-p and the number of CD44highCD4+ T cells were remarkably reduced in telmisartan-treated mice. CONCLUSIONS. Systemic administration of telmisartan significantly suppressed EAU by the inhibition of antigen-specific T-cell activation in the LNs and of leukocyte adhesion in the retina. These results indicate that telmisartan may be a novel therapeutic regimen for patients with endogenous uveitis.

AB - PURPOSE. Angiotensin II type 1 receptor (AT1-R) blockers are used widely for the treatment of patients with hypertension. Recent reports have suggested that AT1-R also plays a key role in various inflammatory conditions. The aim of this study was to examine whether blockade of AT1-R is effective in the suppression of murine experimental autoimmune uveoretinitis (EAU). METHODS. C57BL/6 mice were immunized with human interphotoreceptor retinoid binding protein-derived peptide 1-20 (hIRBP-p). Telmisartan, an AT1-R blocker, was administrated daily by intraperitoneal injection. On day 21 after immunization, the severity of EAU was assessed clinically and histopathologically. With the use of flow cytometry, the activation of draining lymph node (LN) cells was assessed by cell proliferation response against hIRBP-p and by the number of CD44high activated CD4+ T cells present. In addition, mRNA expression of ICAM-1, MCP-1, and IFN-γ in the eye was analyzed by reverse-transcriptase PCR, and the number of retinal adherent leukocytes was counted by retinal perfusion labeling. RESULTS. Telmisartan significantly suppressed EAU clinically and histopathologically. Intraocular mRNA expression of ICAM-1 and MCP-1 was downregulated, and the retinal adherent leukocyte counts were significantly decreased in telmisartan-treated mice compared with vehicle-treated mice. LN cell proliferative responses against hIRBP-p and the number of CD44highCD4+ T cells were remarkably reduced in telmisartan-treated mice. CONCLUSIONS. Systemic administration of telmisartan significantly suppressed EAU by the inhibition of antigen-specific T-cell activation in the LNs and of leukocyte adhesion in the retina. These results indicate that telmisartan may be a novel therapeutic regimen for patients with endogenous uveitis.

UR - http://www.scopus.com/inward/record.url?scp=65549151327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549151327&partnerID=8YFLogxK

U2 - 10.1167/iovs.08-2649

DO - 10.1167/iovs.08-2649

M3 - Article

C2 - 19136706

AN - SCOPUS:65549151327

VL - 50

SP - 2255

EP - 2261

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 5

ER -